DRG Instruments Launches New TBI Test Panel at MEDLAB
DRG Instruments GmbH, a pioneer in immunoassay development for over five decades, is enhancing the landscape of traumatic brain injury (TBI) diagnostics. With the creation of its new division, DRG Neuroscience, the company is set to introduce groundbreaking CLIA tests specifically designed for evaluating suspected TBI. The new tests, featuring a combination of GFAP and UCH-L1, will be available for use on DRG's cutting-edge automated platform, DxDATA™.
Innovative Testing Solutions
The GFAP and UCH-L1 combo tests are engineered to deliver results within just 30 minutes by measuring blood levels of key biomarkers when serum samples are taken within 12 hours of injury. This rapid assessment significantly increases the chances of timely and effective treatment while minimizing the necessity for radiation-based imaging techniques. This approach not only streamlines the diagnostic process but also contributes to better patient outcomes.
Fast and Reliable Assessments
DRG's commitment to advancing healthcare is evident in their latest TBI testing solutions. According to Joerg Schloesser, Managing Director and VP of Commercial, the focus on automation and speedy results allows healthcare professionals to make more informed and quicker decisions regarding patient care. This innovative technology aims to redefine the standard practices surrounding TBI diagnosis and treatment.
Certification and Usability
Both tests are CE-marked, affirming their compliance with international safety and quality standards. They are designed for use in clinical laboratories and are suitable for adults aged 18 years or older, ensuring a broad application within hospital settings across various regions.
MEDLAB Middle East: A Platform for Innovation
DRG will also present this innovative test panel at the upcoming MEDLAB Middle East, an esteemed event happening at the Dubai World Trade Centre. Attendees can find DRG at Hall 1, Booth G50, where the Product Development Team will provide in-depth information and answer queries regarding TBI testing solutions.
About DRG Instruments GmbH
Founded in 1973 and headquartered in Marburg, DRG Instruments GmbH has established itself as a leader in the field of immunoassays, catering to both routine and specialized research applications. With distribution partners spanning over 120 countries, the company has solidified its global presence. DRG is also known for producing the DRG:HYBRiD-XL, a fully automated analyzer that serves both immunoassay and clinical chemistry needs. Committed to quality, DRG operates with ISO 13485 certification and adheres to stringent FDA regulations pertaining to medical devices. For further details about their products and services, visit their website or connect through professional networks.
Frequently Asked Questions
What types of tests is DRG Instruments launching?
DRG Instruments is launching automated CLIA tests for assessing traumatic brain injury (TBI) using GFAP and UCH-L1 biomarkers.
How quickly can results from the TBI tests be obtained?
The tests provide results within 30 minutes if blood samples are collected within 12 hours post-injury.
Are the TBI tests certified?
Yes, the TBI tests are CE-marked and meet Clinical and Laboratory Standards Institute (CLSI) requirements.
Who can use the TBI tests?
The tests are intended for use in clinical laboratories for patients aged 18 years and older.
Where will DRG be showcasing their tests?
DRG will showcase their TBI tests at MEDLAB Middle East in Dubai, from February 3 to 6, at Hall 1, Booth G50.
